Inivata is a Leader in Liquid Biopsy

Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Inivata is a Leader in Liquid Biopsy

Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Our Technology

Liquid Biopsy Unlocking essential genomic information from a simple blood draw to transform the care of cancer patients

InVision® platform

Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients

Learn More

Our Solutions

InVisionFirst®Lung Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients

InVisionFirst®Lung

Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients

Find out More
Radar™ A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform

Radar™

A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform

Discover Radar™

Our Mission

We are transforming the lives of cancer patients and their families through the power of liquid biopsy

Find out More
InvisionFirst Lung - ctDNA Liquid Biopsy Test

Partnerships - for ctDNA Liquid Biopsy Tests

Partnerships

Our Technology - Liquid Biopsy Testing

Our Technology

Contact Us at Inivata

Contact Us

Latest News and Events

Inivata and Collaborators Announce New Data Demonstrating Clinical Potential of its RaDaR™ MRD Test in HR+ HER2- Breast Cancer

21 Jun 2022

Inivata, a leader in liquid biopsy, announces new data in support of its RaDaR assay for the detection of minimal residual disease (MRD) and recurrence in patients with high-risk hormone receptor–positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Read More

More News

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

8 Jun 2022

Marla Lipsyc-Sharf, MD Elza C. de Bruin, PhD Katheryn Santos, BS  Robert McEwen, PhD Daniel Stetson, MS  Ashka Patel, BS  Gregory J. ... Read More

More Publications
WCLC 2022

WCLC 2022

Event expiration date display - 6 - 9 AUG 2022

Location: Vienna, Austria Read More

More Events

Changing Lives

Patients are at the heart of everything we do.

Our first product is for advanced Non-Small Cell lung Cancer and our world-leading tests are already impacting patients’ lives. 

This is the story of the first patient Inivata tested.

Find out More

Transforming the lives of Cancer Patients and Their Families

As a dynamic and innovative company, we focus on the development of ground-breaking technology in a fast-paced and international setting.

Our team of talented and driven individuals work together to combine their energy and expertise in world-class research, product development and commercialization. Join us.

See our latest open roles

 @inivata

August 9, 2022

The @myESMO Annual Meeting takes place next month. Members of #TeamInivata will be on the ground in Paris. For meetings, please contact Vishal Sikri, David Eberhard, Mike Nahorski, Huw Ricketts and Chris Pipinikas. https://www.esmo.org/meetings/esmo-congress-2022 #ESMO22

August 8, 2022

Great to see in @ICR_London, alongside many other key stakeholders, supporting the use of biomarker testing to improve cancer patient diagnosis & care. Read more in this article from @thetimes:
https://bit.ly/3p3fbuk
#diagnostics #oncology #liquidbiopsy

August 4, 2022

At Inivata, our purpose is to help guide more informed #treatments for cancer patients. To hear the story of the first #patient tested with our InVisionFirst-Lung #liquidbiopsy test for #NSCLC, please see below.

https://vimeo.com/699410987

LinkedIn tracking code Twitter tracking code